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ABSTRACT 
AMP-activated protein kinase (AMPK) is emerging as an important regulator of vascular 
function and is proven to affect vascular tone. Here we investigate how AMPK inhibition 
in arteries from both young and aged normotensive Wistar Kyoto (WKY) and 
spontaneously hypertensive (SHR) rats affects contraction in response to different 
receptor agonists. In study 1, isolated common carotid artery (CCA) segments (denuded 
of endothelium) from WKY and SHR were used to determine vasomotor dose-responses 
to the alpha-adrenergic agonist phenylephrine (PE: 10-9.0 - 10-4.5 M) and to the 
thromboxane-prostanoid receptor agonist U46619 (10-9.0 – 10-6.0 M) after incubation with 
no drug (CON); the AMPK inhibitor compound C (CC; 20 µM); the rho-assosiated 
protein kinase (ROCK) inhibitor Y27632 (1 µM); or, a combination of CC and Y27632 at 
the same concentration. PE contraction was suppressed in all groups for all treatment 
conditions (CC, Y, CC+Y; P<0.05) with the combination condition (CC + Y) being 
significantly greater than either individual drug effect in both WKY and SHR CCA, 
though this effect was not completely additive in all groups. Vasomotor responses of 
CCA segments exposed to U46619 under the same incubation conditions exhibited 
significant increase in EC50 when compared to the CON within their respective groups, 
but no significant differences were found in the maximum developed tension (MAX; 
P<0.05). The greatest differences were found between the receptor-mediated responses to 
contraction, with CCA segments of all groups having a higher sensitivity to the TPr 
agonist U46619 than to the alpha-adrenergic agonist PE. Fold increase in EC50 was 
significantly greater in groups subject to PE-induced contraction compared to the same 
responses in U46619 treated groups, with the greatest increase being present in the young 
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WKY (CC+Y; 13.0 ±3.5 fold increase vs. CON). Vasomotor responses were relatively 
unaffected by hypertension and age. In study 2, the vasomotor constriction response to 
separate and combined AMPK and/or HMG-CoA reductase inhibition was measured via 
dose-response curves to PE. Four curves were generated: CON; CC (20 µM); Simvastatin 
(SIM; 5 µM); and, CC + SIM. PE contraction was suppressed in all groups for all 
treatment conditions (CC, SIM, CC+SIM; P<0.05) with the combination condition being 
significantly greater than either individual drug effect. The results suggest that AMPK 
may contribute to modulating the PE contraction response in denuded CCA via 
RhoA/ROCK-dependent and –independent mechanisms.  
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INTRODUCTION!
Thesis Background  
Smooth muscle is an integral part of the cardiovascular system that is responsible 
for the maintenance and control of vascular tone. The magnitude of this tone has global 
effects on the cardiovascular system and is highly involved in the regulation of blood 
pressure, blood flow, tissue oxygenation and nutrient delivery. Regulation of vascular 
tone relies on a complex integration of mechanical and chemical processes the smooth 
muscle cell itself in response to neural, endocrine, paracrine and mechanical signals. 
Pathologies of the smooth muscle, such as aging and hypertension, result in profound 
changes to cellular signaling that can lead to dysfunctional regulation of vascular tone. 
This thesis aims to examine the subcellular mechanisms regulating vascular 
smooth muscle contraction, particularly the possible interaction between two vascular 
smooth muscle (VSM) enzymatic signaling pathways involving AMP-activated protein 
kinase (AMPK) and rho-associated protein kinase (ROCK). This will be examined 
under normal conditions, in both aging and hypertensive models. The following 
provides an introduction to help aid in understanding the rationale behind the 
experiments performed in this thesis. 
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VASCULAR SMOOTH MUSCLE!
Vascular Smooth Muscle Background 
  Vascular smooth muscle (VSM) plays a pivotal role in the complex processes 
regulating blood pressure and flow. In addition to discovery of fundamental 
understanding of vascular function, observing and understanding the mechanisms of 
VSM contraction may elucidate specific changes occurring in disease states and provide 
insight into specific interventions. The latter is particularly important with respect to the 
health of Canadians as, with the exception of cancer, cardiovascular disease accounts for 
the highest cause of mortality (Statistics Canada, 2012). 
 The regulation and control of vascular tone is managed by the dynamic ability for 
VSM to change its contractile state; an integral part of accommodating changes in blood 
flow as well as blood pressure1. VSM’s dynamic ability to accommodate such changes is 
based on its ability to regulate the concentration of and sensitivity to intracellular 
calcium. The initiation of contraction begins either with depolarized-induced contraction 
or the binding of agonists to specific G-protein coupled receptors (GPCRs), which are 
coupled to ion channels and enzymes that can modify specific pathways involved in VSM 
contraction2. 
Calcium influx is the dominant pathway to increase intracellular calcium 
concentration ([Ca2+]i), the facilitator of smooth muscle contraction1. Influx is facilitated 
by a variety of channels including L-type calcium channels3, nonselective cation 
channels4, the sodium-calcium exchanger (NCX) 4 and the sarcoplasmic reticulum4 of the 
smooth muscle5. Second messengers inositol-triphosphate (IP3), diacylglycerol (DAG), 
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cyclic adenosine monophosphate (cAMP), and cyclic guanosine monophosphate (cGMP) 
also affect intracellular calcium levels by modulating these mechanisms5. Increased 
[Ca2+i] results in the formation of the Ca2+-Calmodulin (Ca-CaM) complex, activating 
Ca-CaM-dependent myosin light-chain kinase (MLCK) via phosphorylation of its 
regulatory 20 kDa light chain6. This is followed by a rise in myosin ATPase activity 
which then, in turn, leads to crossbridge cycling and ultimately, VSM contraction2.  
 
Diagram 1: Vascular smooth muscle cell. VSM contraction is initiated via Ca2+-
dependent or independent mechanisms that lead to the phosphorylation of the regulatory 
myosin light-chain, resulting in contraction. 
 
Though VSM contraction is regulated by [Ca2+i] and its affinity for calmodulin, 
sensitivity to calcium is also modulated by GPCR activity7. GPCR activity is also linked 
to the Rho-mediated modulation of the balance between MLCK/MLCP activity6, an 
important downstream pathway involved in the regulation of vascular tone.  
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A variety of agonists can initiate calcium sensitization via RhoA and its 
downstream effectors. Agonist-induced activation of thromboxane-prostanoid (TPr) 
GPCR requires active guanosine exchange factors (GEFs) 8, which are responsible for 
catalyzing the exchange from inactive RhoA!GDP to RhoA!GTP9. The subsequent result 
is the binding of RhoA!GTP to rho-kinase (ROCK), inducing a conformational change 
and activation of the ROCK enzyme10. ROCK phosphorylates specific site threonine sites 
(Thr696,853) on MLCP7, resulting in its inhibition and decreased MLCP activity, 
increasing the relative MLCK/MLCP activity ratio7, thus increasing the magnitude of 
contraction. 
GPCRs can also initiate contraction independent of RhoA activation. For instance, 
the α-adrenergic receptor can also initiate signaling cascades that ultimately result in 
smooth muscle contraction (Diagram 1).  Stimulation of α-adrenergic receptors leads to 
stimulation of Gq GPCR, activating phospholipase C (PLC), leading to the production of 
phosphatidylinositol-4,5-bisphosphate (PIP2) 11. PIP2 then stimulates the production of 
IP3, resulting in the influx of calcium which subsequently initiates formation of Ca-CaM 
complex, leading to MLCK activation, increased RLC phosphorylation, and enhanced 
VSM contraction12. 
Following the light-chain phosphorylation peak between 30-60 seconds, we 
observe a drop in phosphorylation while tone is maintained1. This is an indication that 
elevation in myosin light-chain phosphorylation is not essential for sustained, tonic VSM 
contraction and the magnitude of tone is variable, depending on the activation of kinase 
and phosphates acting on MLC2. One such kinase, AMPK, has been implicated in having 
a direct role in the regulation of MLC activity13. 
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AMP-Activated Protein Kinase (AMPK) 
AMP-activated Protein Kinase 
In addition to the specific pathways described in the previous section, a variety of 
enzymes can affect the signaling pathways converging on MLCK/MLCP-mediated 
contraction. Adenosine monophosphate-activated protein kinase, or AMPK, is classically 
recognized as an enzyme responsible for maintaining cellular energy homeostasis across 
a variety of eukaryotic cell types14. It was first identified in 1973 as a kinase of both 
acetyl-CoA carboxylase15 and HMG-CoA reductase16 before being described as the 
allosteric kinase “AMP-activated protein kinase” 17. 
Historically, AMPK was studied for its dynamic ability to detect alterations in 
cellular energy levels, mainly changes in the AMP:ATP ratio17-19. This kinase, which is 
highly sensitive to levels of AMP and ATP, swiftly responds to such changes in cellular 
energy levels by activating energy production pathways and/or inhibiting energy 
consumption pathways19. In addition to nucleotide balance, there are several stimuli that 
influence AMPK activity including intracellular calcium20, hormones21 and cytokines21, 
with additional influence of chronic mechanisms controlling AMPK transcription and 
protein synthesis22.  
 
AMPK Structure and Function 
 The structure of AMPK can be a main determinant of its activity during cellular 
stress20. AMPK is composed of three subunits; the catalytic  subunit in addition to its 
regulatory  and  subunits14. Both the  and  subunits have 2 isoforms while the 
 subunit has 3 isoforms, allowing a total of 12 possible subunit conformations23. 
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Distinct combinations of these subunits affords the enzyme its dynamic ability to 
accommodate changes in cellular energy.  
 AMPK activity can be controlled, in part, by covalent mechanisms that 
phosphorylate its catalytic  subunit (which must occur for enzyme activation) or via the 
allosteric binding of AMP to the   subunit24. Allosteric binding results in a 
conformational change of the protein that not only increases its affinity for 
phosphorylation by upstream kinases20 but also decreases its potential for 
dephosphorylation via PP2C23,25. Though the allosteric role of AMP is important to 
AMPK activity, the bulk of the enzyme’s activation results from phosphorylation of the 
 subunit at its Thr172 residue19. This phosphorylation is achieved through activation of 
upstream kinases LKB1and CaMKK23, both of which transfer a phosphate group from 
ATP to AMPK, though it should be noted that AMP itself does not directly activate these 
upstream kinases26.  
 
AMPK in Research 
 During periods of increased energy demands, vasodilation is an essential 
mechanism that regulates systemic blood flow27. As an energy sensing kinase, AMPK 
could be involved in management of vascular tone. AMPK was first demonstrated to 
have a role in the in vitro regulation of vascular tone by Rubin et all in 200528. It was 
found that hypoxia-induced AMPK activation was associated with vasodilation in 
endothelium-denuded isolated porcine coronary arteries28.  Goriand et al in 200729 then 
observed AICAR (AMPK activator) dose-dependent vasodilation in the isolated aortic 
rings of mice, an effect that was severely blunted in the AMPK1
-/- animal model29. This 
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demonstrated that AMPK activation of the α1 subunit induces vasorelaxation in the aortic 
smooth muscle of mice. In 2011, Ford and Rush30 showed that endothelium-dependent 
vasorelaxation to AICAR is enhanced in SHR, an animal model of hypertension, and is 
NO and EDCF dependent. One of the most interesting observations with respect to 
AMPK research is the novel finding that AMPK activity has been linked to specific 
GPCR’s31,32. This provides powerful evidence to suggest that AMPK plays an important 
role in the maintenance and regulation of vascular tone, and the influence of AMPK 
could be altered in cardiovascular disease states, making it a treatment target in specific 
disease models.  
 
AMPK in Pathophysiology 
Documentation shows that a variety of vasoactive factors modulate the activity of 
AMPK in vascular smooth muscle. Such factors include hypoxia, free radicals, 
bradykinin, adiponectin, thrombin, metformin, resveratrol and AICAR33,34. With so many 
influences on activity, these vasoactive factors could play a role in the manner in which 
AMPK is involved in regulating contraction in VSM. 
Impairment of AMPK activation, whether it be diminished responsiveness of 
AMPK to signaling cascades or changes in basal activation, occurs in a variety of disease 
states, particularly metabolic and cardiovascular disease, and in the arteries of aged rats35. 
Zucker diabetic fatty rats and aged rats both have depressed AMPK activation, indicating 
dysregulation of AMPK function36. AMPK basal activity is also blunted in SHR rats 
compared to WKY rats, though it is unknown whether or not the ability of these rats to 
activate AMPK is compromised30. Characterizing this enzyme and its mechanism of 
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action with respect to downstream signaling pathways (like Rho-mediated MLCP 
inhibition) involved in the regulation of vascular tone would provide great insight 
towards the role AMPK plays in regulating contraction in disease states like hypertension 
and aging. 
 
SALICYLATES 
In addition to modulating vascular reactivity in disease states, AMPK is also 
influenced by a variety of pharmacological agents. One group of compounds, salicylates, 
an acid derived from the bark of a willow tree, was of particular interest, with it having 
several proven effects and uses in medicine and health37. Initially, a paper describing the 
effect of salicylates on AMPK in HEK and mouse liver cells38 peaked my interest in 
salicylates and their possible influence on AMPK activity in VSM. The literature clearly 
demonstrated that increasing doses of salicylate were directly correlated to an increase in 
AMPK was activity38. With salicylates having a dose dependent effect on AMPK activity 
in cultured cells, investigation of this effect in VSM could provide valuable insight 
towards another potential method of pharmacologically modulating AMPK activity. Pilot 
work using isolated rat CCA segments examined the effect of increasing doses of 
salicylates and their effect on relieving agonist-induced contraction (see appendix, figures 
S1 and S2). After demonstrating that increasing doses of salicylates led to vasorelaxation 
in these CCA segments, our results were excitingly promising. Further research was 
conducted to follow up on this curiosity, with examination of any potential effects 
salicylates may be having on the VSM contraction taking priority. It became evident that 
salicylates were already found to act through the RhoA/ROCK pathway39, an important 
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downstream regulator of vascular tone that is highly involved in VSM contraction11. The 
realization that salicylates work through RhoA/ROCK during VSM contraction and 
relaxation, coupled with their potential ability to activate AMPK led to the inception of 
an idea; could AMPK and ROCK activity be linked to one another during the regulation 
of VSM contraction? If an effect was present, was the effect of one enzyme –dependent 
or –independent of the other? These curiosities eventually led to this thesis project 
examining the subcellular mechanisms responsible for influence of AMPK activity on the 
control and regulation of vascular tone and the potential involvement of ROCK activity. 
 
RHOA AND RHO KINASE 
RhoA and Rho-kinase Function 
RhoA and it’s downstream effector, Rho associated protein kinase (ROCK), have 
been identified to play crucial roles in regulating vascular smooth muscle activity6. The 
presence of specific G-protein receptors found on vascular smooth muscle membranes are 
directly correlated to smooth muscle contraction. Such receptor proteins are Gq, G
12,13 and G1,2, all of which are linked to RhoA/ROCK activity40-42.   
Stimulation of the G12,13 in smooth muscle results in RhoA activation via 
RhoGEF’s that phosphorylate Rho-GDP to form RhoA-GTP11. RhoA-GTP then activates 
ROCK, a protein serine/threonine kinase that is highly involved in smooth muscle 
contraction43. Specific functional motifs are essential to function of the enzyme, including 
a rho-binding carboxyl terminal domain that forms an autoinhibitory region that reduces 
the activity of the kinase11. This kinase activity can be enhanced by rho binding but only 
in an activated GTP bound form. GTP binding subsequently leads to ROCK activation 
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and the phosphorylation of the regulatory subunit of MLCP, inhibiting its ability to 
dephosphorylate MLC and relieve contraction44.  Regulation of ROCK activity is 
essential to the regulation of MLC activity and thus contraction. 
 
RhoA/ROCK in Pathophysiology 
 Research has implicated that variations in the RhoA/ROCK activity and signaling 
are responsible for increased peripheral vascular resistance in hypertension12,45. Increased 
RhoA activity is associated with enhanced ROCK activation, leading to hypertension12. 
Animal studies using spontaneously hypertensive rats (SHR) showed that Rhoa/ROCK-
mediated Ca2+ sensitization is elevated in hypertension and when compared to smaller, 
resistance arteries, conduit arteries appear to have a greater contribution from 
RhoA/ROCK signaling pathways46. Analysis of gene expression in stroke-prone SHR 
(SPSHR) animals has also implicated upregulated RhoA/ROCK activity as a 
consequence, not cause, of hypertension44. Dysfunction in protein synthesis, transcription 
signaling and calcium handling have all been linked to RhoA/ROCK in aging 
conditions47-49, though it is relatively unknown how RhoA/ROCK function is affected by 
aging in the VSM of conduit arteries of WKY and SHR animals.  Understanding the 
potential dysfunction of ROCK signaling is essential when considering the effect AMPK 
inhibition may have on the RhoA/ROCK signaling pathway in normal and disease states. 
 
STATINS!
 Statins inhibit the enzyme 3-hydroxy-3-methylglutaryl coenzyme reductase 
(HMG-CoA reductase), a rate-limiting enzyme essential to cholesterol biosynthesis in the 
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mevalonate pathway50. Statins are classically used to treat cardiovascular disease through 
manipulation of LDL, as reduced cholesterol synthesis forces hepatocytes to upregulate 
expression of LDL receptors leading to enhanced clearance of LDL from circulating 
plasma51.  
Statins have been implicated in a variety of cellular signalling mechanisms in 
vascular smooth muscle including reduction of reactive oxygen species52, reduction of 
inflammatory signaling hormones53 and anti-thrombotic effects54. However, little 
research regarding the role of statins in modulating vascular smooth muscle contraction is 
known. Uhiara et al. in 2012 demonstrated that simvastatin modulated β-adrenoreceptor-
mediated vasodilation in porcine coronary arteries55. Seto et al. later demonstrated that 
simvastatin also inhibits potassium ATPase channels in porcine coronary arteries leading 
to impaired vasorelaxation56. Although limited, research suggests that the signaling 
mechanisms involved in vascular smooth muscle HMG-CoA reductase inhibition are 
involved in the regulation of contraction56. Pilot work in our laboratory has demonstrated 
that simvastatin (an HMG-CoA reductase inhibitor) modulates VSM 1-adrenergic 
induced contraction. Whether these effects are specific to HMG-CoA reductase activity 
or whether they are pleiotropic in nature is yet to be seen. 
 
PATHOLOGY OF VASCULAR SMOOTH MUSCLE 
Aging and the Cardiovascular System 
Studies have shown that age is the leading risk factor for the development of 
cardiovascular disease57-59. With normal function, the heart acts as a reciprocating pump 
that forces blood into the vasculature, which, in turn, is responsible for adequately 
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distributing blood to specific tissues of the body60. Continuous blood flow is facilitated 
by the elastic conduit arteries that expand and store the elastic energy generated by the 
left ventrical during systole. After the aortic valve closes, the artery recoils and releases 
its elastic energy, pumping the remaining arterial blood through the cardiovascular 
system during diastole. As age progresses, arteries become stiffer and less compliant49, 
hindering their ability to furnish the continuous blood flow during diastole as a result of 
their decreased capacity to store the energy generated during systole. This loss of 
function has the potential to evoke serious complications, such as hypertension and 
atherosclerosis, and can exacerbate already existing conditions59,61. 
Age-related changes in the elasticity and compliance of arteries results from 
changes in the structural composition of the vascular wall60. Normal arteries are made up 
of three distinct layers: the intima, media, and adventitia. The intima is the innermost 
layer and contains the endothelium and a basement membrane that is mostly collagen in 
its composition62. Consequently, the intima has little to do with the structurally elastic 
properties of the blood vessel. The media and intima are composed of collagen, elastin 
and vascular smooth muscle cells. The elastic fibres found in the media are comprised of 
up to 90% elastin in concert with at least 19 other proteins63. Variations of elastin-
collagen composition, along with muscularity/VSM content determine the overall non-
linear elastic properties of the artery. Farther away from the heart, a decrease in elastin 
content and an increase in muscularity is observed when capacitance vessels transition 
towards becoming resistance vessels64. This concept is essential in the case of this study, 
as the focus is on the common carotid artery, a capacitance vessel responsible for 
approximately 80% of the brain’s blood flow65. 
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In aging and vascular disease, the intima thickens as an accompanying increase in 
lumen diameter also occurs. A decrease in elastin content and increase in collagen 
content has a compounded effect and ultimately results in decreased large artery 
compliance and increase in stiffness with age49,66. These pathological effects can also lead 
to more severe conditions like left ventricular hypertrophy and hypertension. 
 
HYPERTENSION 
Systemic hypertension is characterized by increased vascular resistance resulting 
from increased contractility, thrombosis, and structural remodeling of the arterial wall, 
mainly smooth muscle cell proliferation2,44,61. Such characteristics suggest an imbalance 
between signaling factors that are responsible for maintaining the normal relationship 
between vasodilation and vasoconstriction as well as growth inhibitors and mitogenic 
factors67. These imbalances are usually the consequence of endothelial dysfunction or 
injury to the vascular wall, with imbalance between vasoactive signaling factors causing 
much of the dysfunction68.   
The balance between two of these important vasoactive factors, prostacyclin and 
thromboxane, is essential for proper regulation of the VSM contractile state. Both are 
metabolites of aracadonic acid but have opposing effects with prostacyclin initiating 
vasodilation and thromboxane being a potent vasoconstrictor69. Increased levels of 
circulating thromboxane metabolites and decreased production of prostacyclin synthase 
shifts the balance in favour of vasoconstriction, an effect that is more prevalent in 
hypertension70. 
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On a molecular level, VSM cells undergo a variety of changes in signaling 
cascades during aging that eventually lead to altered responses to agonist-induced 
contractile stimuli. Age provokes a loss of receptors in vascular smooth muscle cells71 
and can result in decreased agonist potency. In rat aorta, a decreased maximal contractile 
response is observed in aging, which can be attributed to a decrease in receptor density 
with specificity to α1-adrenoreceptors72. Aging has also been associated with inhibition of 
matrix metallo-proteases, proteins responsible for maintaining the structural integrity of 
the vessel wall60. This inhibition is accompanied by increased levels of circulating pro-
inflammatory molecules, like IL-6 along with other leukocyte stimulating factors73. This 
leads to increases in ECM matrix protein synthesis and can result in intimal 
hypertrophy74. VSM hypertrophy is also observed in aging, stemming from continuously 
elevated pressure, indicating that mechanical stress can also act a as a regulator of VSM 
cell function and structure75. With a variety of age related factors acting on VSM, 
observing changes in the contraction profile of isolated WKY/SHR CCA segments could 
provide valuable insight regarding the pathological significance of age-related changes in 
contraction. 
 
ENDOTHELIAL INFLUENCE ON VASCULAR TONE 
The vascular endothelium has demonstrated a variety of effects on signaling 
mechanisms responsible for the maintenance and control of vascular tone and has swiftly 
emerged as an interesting target for current vascular research2,30,76. Endothelial 
dysfunction resulting from aging, hypertension and a variety of other disease states makes 
the endothelium an ideal target for pharmacological intervention. However, for all intents 
 15 
and purposes of this project, ALL carotid artery segments were excised and denuded of 
an endothelium. This allowed us to attribute any of the observed changes to the vascular 
smooth muscle alone, as the potentially confounding influence of the endothelium was 
not present during experimentation.  
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SUMMARY 
 In summary, the effect of AMPK inhibition either separately, or combined with 
ROCK inhibition, is currently unknown in isolated rat CCA segments. Examining the 
vasomotor response of these isolated segments after incubation with specific enzyme 
inhibitors could provide valuable insight regarding the regulation of VSM contraction, 
particularly the possible interaction between two VSM enzymatic signaling pathways 
involving AMPK and ROCK (see diagram 2). Discerning the role of AMPK in normal, 
hypertensive and aged models would aid in not only developing a sound understanding of 
their independent function, but it would also develop an understanding of their function 
with respect to each other.  
 
Diagram 2: Potential mechanisms of action for AMPK. Vascular smooth muscle cell 
describing the potential sites of action for AMPK and the HMG-CoA reductase inhibitor 
Simvastatin in the regulation of contraction. 
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EXPERIMENTAL DESIGN 
 
Study 1 – Investigation of CCA vasomotor contractile responses to separate or combined 
AMPK and ROCK inhibition 
 
Rationale 
Pilot work from my original thesis topic of salicylates (see supplemental material; 
S1, S2) indicated that AMPK activity may play a role in mediating the influence of 
salicylates on the regulation of the RhoA/ROCK contractile pathway. Examining these 
effects in isolated CCA WKY segments led to the current work examining the effect of 
combined, direct AMPK and ROCK inhibition.  
Receptor mediated contraction can be regulated by RhoA activation and 
downstream ROCK-mediated MYPT1 phosphorylation, resulting in MLCP inhibition76. 
If AMPK plays a role in mediating RhoA/ROCK activity, then AMPK’s inhibition 
should affect the VSM response to RhoA/ROCK inhibition as well. AMPK and ROCK 
activity have been linked to GPCR activity in the regulation of vascular tone11, 
suggesting some sort of cross-talk between the modulation of vascular tone by these 
kinases. Whether AMPK acts independently or dependently on ROCK is yet to be 
established, though it can be hypothesized that AMPK does modulate ROCK activity in 
response to pharmacologically induced contraction. The use of two separate agonists (the 
alpha-adrenergic agonist PE and the thromboxane-prostanoid receptor agonist U46619) 
will aid in examining any receptor mediated differences present. 
We also know that age and hypertension are associated with decreased levels of 
basal AMPK activity and could also be involved in modulating the vascular response to 
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contraction. These two conditions are also associated with increased ROCK signaling 
activity. Examining their effect on modulating contraction could also be beneficial for 
characterizing the role of AMPK in the regulation of VSM contraction.  
 
Objectives 
The objective of thesis study 1 was to confirm the mechanical vasomotor response 
of isolated WKY carotid artery segments to AMPK and/or ROCK inhibition. This study 
was also conducted to further expand on that knowledge and elucidate whether or not 
AMPK played a role in ROCK and it’s ability to mediate vascular tone in response to 
agonist-induced contraction. The second objective of thesis study 1 was to examine the 
effect of aging and hypertension on the vasomotor response of isolated SHR and WKY 
CCA segments to AMPK and/or ROCK inhibition. The final objective of study 1 was to 
examine whether or not any receptor mediated differences were present during the 
vascular response to separate or combined AMPK and ROCK inhibition. Comparison of 
response to the α1-adrenergic contractile agonist PE and the thromboxane-prostanoid 
receptor agonist U46619 was the approach used to elucidate the presence of any receptor-
mediated differences. Investigation using these objectives would aid in determining the 
role of AMPK and RhoA/ROCK in modulating contraction in response to vascular 
agonists. 
 
Anticipated results and importance of study 1 
The completion of thesis study 1 would clarify: 1) the influence of AMPK 
inhibition and its potential to modulate RhoA/ROCK activity in pharmacologically-
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induced VSM contraction and 2) how age and hypertension can affect the ability of 
AMPK to modulate a the downstream RhoA/ROCK activity pathway, either separately or 
in combination and 3) any receptor-mediated differences that may be present in purposes 
(1) and (2).  
 
Study 2 – Investigation of CCA vasomotor contractile responses to separate or combined 
AMPK and HMG-CoA reductase inhibition 
 
Rationale  
 AMPK was initially discovered as a kinase of HMG-CoA reductase and has been 
shown to activate and phosphorylate HMG-CoA reductase, inhibiting its activity77. 
HMG-CoA inhibition has also been shown to downregulate Angiotensin II-induced Rho 
activation, and consequently, MYPT1 phosphorylation, in cultured VSM cells78. With 
implications in both the energy-sensing role of AMPK and the contraction mediating role 
of ROCK, HMG-CoA reductase is a strong candidate for pharmacological manipulation 
of agonist-induced contraction in VSM.  
Using wire myography, this study aims to examine the potential effect that AMPK 
activation has on HMG-CoA reductase activity in VSM. Through the use of the specific 
AMPK inhibitor compound C (CC), and the HMG-CoA reductase inhibitor simvastatin 
(SIM), this study will observe and investigate the mechanical responses to 
pharmacologically-induced contraction. 
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Objectives 
The objective of thesis study 2 was to examine vasomotor response of isolated 
WKY CCA to HMG-CoA reductase inhibition using the HMG-CoA reductase inhibitor 
simvastatin.  
 
Anticipated results and importance of study 2 
The completion of this study would clarify: 1) the mechanical vascular response 
to HMG-CoA reductase inhibition in smooth muscle alone and 2) the influence of AMPK 
inhibition on HMG-CoA reductase activity in smooth muscle.  
 
HYPOTHESES 
Study 1: 
1. Combined and separate AMPK and ROCK inhibition will increase the EC50 and 
decrease the maximum tension developed in the contractile responses to the VSM 
agonists PE and U46619 across all treatment groups. 
2. Hypertension and age will enhance the EC50 and MAX tension VSM contractile 
response to agonist-induced contraction with a greater magnitude of difference in the old 
SHR compared to young WKY. 
3. The α1-adrenergic receptor agonist phenylephrine (PE) and the thromboxane receptor 
agonist U46619 will exhibit receptor-mediated differences between all treatment groups 
(SHR/WKY, old/young). 
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4. The influence of AMPK inhibition and ROCK inhibition will be more pronounced in 
response to the TPr agonist-induced contraction since this signaling pathway directly 
affects ROCK activity. 
 
Study 2 
1. AMPK activity in vascular smooth muscle modulates RhoA/ROCK activation via 
HmG-CoA reductase inhibition. 
2. HMG-CoA reductase inhibition cause a blunted response to agonist-induced 
contraction. 
 
 
MATERIALS AND METHODS 
Animal Model 
 In this study, Wistar-Kyoto rats (WKY) and spontaneously hypertensive rats 
(SHR) will be used as a model for studying the effects of essential hypertension. 
 WKY rats were first bred in 1963 by Okamotao and Aoki79 and commonly serve 
as control strain animals, especially when compared to SHR animals. The strain was 
further developed at the National Institute of Health in the United States of America via 
inbreeding within the colony using brother and sister rats67.  
SHR rats are genetic descendants of the WKY animals with substantial 
phenotypic variation resulting in elevated blood pressure. These animals typically reach 
hypertensive plateau at 16-24 weeks of age67.  Male animals develop hypertension more 
rapidly than females and experience hypertrophic vasculature resulting in an increase in 
total peripheral resistance80. Within the strain, intra-individual changes are rare and 
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relatively uniform when they do occur, making SHR animals ideal candidates for 
modeling human essential hypertension. 
 
Animal Characteristics 
Male WKY (n=56) and SHR (n=45) rats were obtained from the University of 
Waterloo breeding colony. Animals were classified as either adult (18-26 weeks of age) 
or old (>52 weeks) and housed in a temperature and humidity controlled environment 
with access to standard chow (Harlan Laboratories) and tap water ad libitium. Animals 
were acclimated to a twelve-hour reverse light cycle. Before tissue was collected for 
measurement and analysis, animals were anesthetized via intraperitoneal injection of 
sodium pentobarbital (50-65 mg/kg of body weight; Bimeda-MYC, Cambridge, Ontario). 
Sedation level was gauged based on withdrawal reflex in response to a toe-pinch, with a 
complete lack of withdrawal indicating an appropriate level of sedation. Prior to 
assessment of vasomotor responses in isolated vessels, animals were sacrificed via 
exsanguination. All procedures involving rats were approved by the University of 
Waterloo Animal Care Committee and were in accordance with the guidelines of the 
Canadian Council on Animal Care. 
 
Vasomotor Response Assessment in Isolated Vessels 
For this study, vasomotor responses were collected and measured using wire 
myography as the primary means of investigation. A general procedure for conducting 
wire myography in our integrative vascular biology lab was followed30,76,81. Specifics of 
the pharmacological treatment of the isolated vessels was the main difference between 
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each individual protocol. Following sedation and exsanguination, excised CCA segments 
were placed in a 4°C solution of Krebs Bicarbonate buffer (concentration (mmol/L): 
131.5 NaCl, 5 KCl, 25 CaCl2, 1.2 NaH2PO4, 1.2 MgCl2, 0.025 EDTA, 13.5 NaHCO, 11.2 
Glucose). Cleaned arteries were cut into 2-mm segments using a surgical blade under a 
dissecting microscope (Zeiss; VWR, Mississauga, Ontario) before being isometrically 
mounted on a wire myography unit (vascular myography unit, Radnoti Glass Technology 
Inc., Monrovia, California). In all instances, the endothelium was removed by inserting a 
thin, tungsten wire through the 2-mm vessel segment and rolling it on Whatman blotting 
paper soaked with 4°C Krebs Bicarbonate buffer. This was confirmed by observing a 
dose-dependent relaxation response to the endothelium-dependent vasodilator, ACh. If 
<5% vasodilation, compared to maximum PE tension developed, was observed at any 
concentration of ACh, the vessel was considered denuded (see appendix for data 
supporting the efficacy of this technique). Segments were then threaded onto a wire 
triangle and suspended from a force transducer (model MLT0201/D, ADI Instruments) 
before being threaded through a fixed wire foot and submersed in Krebs-bicarbonate 
buffer at 37°C bubbled with 95% O2 and 5% CO2.  Passive tension was applied and 
vessels were equilibrated via washing in fresh buffer before being ramped to 2.85 grams 
(optimal tension previously determined by Denniss and Rush, 200976) of tension for 10 
minutes. This process of washing with fresh buffer and ramping to 2.85 grams of tension 
was performed 3 times. Viability was assessed using the addition of 60mM of KCl to 
generate a depolarization-dependent contraction, which was assessed for 30 minutes. 
After this 30-minute period, vessels were washed with fresh buffer 3 times with a 5 
minute waiting period following each wash. This 30 minute KCl contraction protocol, 
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followed by washout to baseline tension, was repeated one more time before vessels were 
subjected to one of the specific experimental protocols as detailed in the following 
section. 
 
Measurement of AMPK and ROCK contributions to agonist-induced VSM contraction 
After the equilibration period, vessels were subject to four separate incubation 
conditions; No drug (control); 30 minute incubation with AMPK inhibitor compound C 
(CC; 20 µM); 30 minute incubation with the ROCK inhibitor Y27632 (1µM); or a 30 
minute incubation with both CC(20 µM) and Y27632 (1 µM). The concentration of 20 
µM for compound C was based on the work of R.J. Ford and J.W. Rush30, where the 
same concentration was found to have a maximal inhibition effect on AMPK. Pilot work 
examining the effect of Y27632 incubation on VSM contraction led to the use of a 
concentration of 1 µM (see appendix for data). 
Following the incubation period, vessels were subjected to one of two different 
contractile agonists: the α1-adrenergic receptor agonist phenylephrine (PE) with 
concentrations ranging from 10-9.0 to 10-4.5  mmol/L or the thromboxane receptor agonist 
U46619 with concentrations ranging from 10-9.0 to 10-6.0 mmol/L. Both contractile 
agonists were administered in a stepwise fashion, with concentration increasing by a half 
log per dose until a plateau in constriction was achieved. 
 
Measurement of HMG-CoA reductase contribution to agonist-induced VSM contraction 
 Wire myography was used to examine the potential modulating effect statins may 
have on the VSM constriction response and its potential interaction with either the 
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AMPK or ROCK contractile pathways. After equilibration, vessels were subjected to four 
separate conditions; No drug (control); 30 minute incubation with AMPK inhibitor 
compound C (CC; 20 µM); 30 minute incubation with the statin simvastatin (SIM; 5 µM); 
or a 30 minute incubation with both CC(20 µM) and SIM (5 µM). Pilot work determined 
5 µM as the optimal incubation concentration of simvastatin, with doses greater than 5 
µM having no significantly greater effect to PE-induced contraction (see appendix for 
data).  
After this incubation period, vessels were subjected to 2 different contractile 
agonists: the α1-adrenergic receptor agonist phenylephrine (PE) with concentrations 
ranging from 10-9 to 10-4.5  mmol/L and the thromboxane receptor agonist U-46619 with 
concentrations ranging from 10-9.0 to 10-6.0 mmol/L. Both contractile agonists were 
administered in a stepwise fashion, with concentration increasing by a half log per dose 
until a plateau in constriction was achieved. 
 
Statistics 
 Contraction dose-response curve data was expressed as developed tension (peak 
tension – resting tension) in milligrams or as a percentage relative to the peak tension 
developed during the administration of 60 mM KCl ((dose tension – resting tension)/(KCl 
peak tension – resting tension)). Dose-response cruves were fit into a sigmoidal model 
with a bottom boundary of 0 (GraphPad Prism version 6.0b, San Diego, CA). Curve 
characteristics (EC50, maximum amplitude of tension, area under the curve) were 
generated for each CCA segment based on their respective dose-response curves.  All 3 
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parameters were measured for all treatment groups in both thesis study 1 and thesis study 
2.  
 Comparisons between curves were assessed with 3-way ANOVA analysis 
(incubation*strain, incubation*age, age*strain, incubation*strain*age) using SPSS 
software (version 11.5.1) to examine treatment effects within groups (aging or 
hypertension groups). Groups were compared statistically in singular comparison 
conditions (age comparison, hypertension comparison, control vs. separate inhibition, 
control vs. combined inhibition) using multiple and unpaired t-tests (P<0.05; GraphPad 
Prism version 6.0b). All values are expressed as a ± SEM. 
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RESULTS 
For the reader, the results section will be organized in the following way: 
 
Study 1 
First, the effects of PE-induced contraction in isolated CCA for study 1 will be 
established by examining the effects observed in young WKY CCA segments. This will 
provide a “normal” reference point to compare other group. Following the response to 
PE-induced contraction in young WKY, any potential hypertensive effects will be 
described. This will include a comparison of both the young and old cohorts (WKY vs. 
SHR in young and old groups). Next, an age comparison will be made in both WKY and 
SHR groups, completing the comparisons for the PE-induced contraction portion of the 
study. 
The results from the U46619-induced contraction will be presented in the exact 
same fashion using the exact same comparisons as the PE-induced study with the only 
exception being the use of U46619 as a contractile agonist instead of PE. 
Following the descriptive statements explaining the results of the agonist-induced 
contraction components of the study, a comparison explaining receptor-mediated 
differences will be made. This comparison will examine the changes in EC50 compared to 
the respective controls as well as the changes in MAX developed tension compared to the 
controls. 
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Study 2: 
With PE being the only agonist and old WKY being the only treatment group, the 
presentation of these results will be a straightforward analysis of the EC50, MAX and 
AUC response to PE-induced contraction in response to separate or combined AMPK 
and/or ROCK inhibition. 
 
 
Rat characteristics and classification 
Based on availability, both WKY and SHR animals were classified into two 
different age groups; young (20-30 weeks) and old (48+ weeks) (see tables 1-3 for 
average ages and body weight).  
 
VASOMOTOR RESPONSE TO ALPHA-ADRENERGIC AGONIST PE 
The vasomotor contraction response to separate and combined AMPK and/or 
ROCK inhibition was measured via dose-response curves to the α1-adrenergic receptor 
specific agonist PE in the presence or absence of pharmacological antagonists. Four 
curves were generated: CON; CC; Y; and, CC + Y. Each curve was characterized using 
three parameters: half of the maximal effective concentration (EC50); maximum 
vasoconstriction (MAX) and the area under the curve (AUC). 
 
Vasoconstriction in young WKY 
The EC50 for all three drug incubation conditions (CC, Y, CC+Y) was 
significantly greater than that of the control (CON; p<0.05) with both the separate CC 
and Y conditions being significantly lower compared to the combined CC+Y inhibition 
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condition (p<0.05)(table 4). There was no significant difference between the separate CC 
and Y incubation conditions. 
The MAX developed tension in grams was also measured, with the Y and CC+Y 
drug incubation conditions being significantly lower than the control (p<0.05)(table 4). 
The separate CC and Y incubation conditions produced significantly greater tension 
developed compared to the combined CC+Y condition (p<0.05)(table 4). There was no 
significant difference between the separate CC and Y incubation conditions. 
The AUC for the Y incubation condition and the combined CC+Y condition was 
significantly lower than that of the control condition (CON; p<0.05)(table 4). The 
separate CC and Y incubation conditions had significantly greater AUC compared to the 
combined CC+Y condition (p<0.05)(table 4). There was no significant difference 
between the separate CC and Y incubation conditions. 
 
 
HYPERTENSION VASOMOTOR RESPONSE TO THE ALPHA-ADRENERGIC 
RECEPTOR SPECIFIC AGONIST PE 
Young WKY vs SHR 
In comparison to their age-matched WKY, the young SHR group exhibited a 
similar increased EC50 response compared to control, with separate incubation conditions 
being significantly different from the control but not to each other and the combined 
condition being significantly different from the separate conditions (table 4). This was 
also true of the observed AUC changes, but not the MAX in young SHR (table 4) 
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In the EC50 response of young WKY and SHR, only the CON incubation 
condition was significantly lower in SHR compared to WKY (SHR: 14.5±1.1 nM vs. 
WKY: 21.7±3.2 nM, p<0.05; table 4). The SHR also developed significantly greater 
MAX tension in the separate Y incubation condition (SHR: 1.3±0.1 grams vs. WKY: 
1.1±0.0 grams, p<0.05; table 4) as well as the combined CC+Y incubation condition 
(SHR: 1.2±0.0 vs. WKY: 0.9±0.1, p<0.05; table 4). AUC was significantly greater in 
SHR for only the combined CC+Y incubation condition (SHR: 184.2±5.6 units vs. 
WKY: 157.4±8.2 units, p<0.05; table 4). 
No significant differences between old WKY and SHR in EC50, MAX or AUC 
were present for any incubation condition (table 5). 
 
AGING VASOMOTOR RESPONSE TO THE ALPHA-ADRENERGIC SPECIFIC 
AGONIST PE 
 
WKY 
In the EC50 response of WKY, the CON, CC and Y incubation conditions were 
significantly lower in young WKY compared to old WKY (table 6). No significant 
differences in MAX or AUC were present between young and old WKY.  
 
SHR 
In the EC50 response of SHR, all incubation conditions (CON, CC, Y, CC+Y) 
were significantly lower in young SHR compared to old SHR (table 7). AUC was 
significantly lower in the old SHR for all incubation conditions (table 7).  
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3-WAY ANOVA ANALYSIS OF CURVE PARAMETERS IN RESPONSE TO PE-
INDUCED CONTRACTION 
EC50 
 3-Way ANOVA analysis revealed that only incubation (separate or combined 
AMPK and/or ROCK inhibition) and aging had significant effects on the EC50 response 
to PE-induced contraction (table 8). 
 
MAX 
 3-Way ANOVA analysis revealed that MAX tension in response to PE-induced 
contraction significantly was significantly affected by incubation and aging. It also 
revealed that there was an interaction effect present between aging and hypertension 
(table 9). 
 
AUC 
 3-Way ANOVA analysis revealed that PE-induced contraction was significantly 
affected by both incubation and aging. There was also an interaction effect present 
between aging and hypertension (table 10). 
 
VASOMOTOR RESPONSE TO THE THROMBOXANE PROSTANOID RECEPTOR 
AGONIST U46619 
 
The vasomotor constriction response to separate and combined AMPK and/or 
ROCK inhibition was measured via dose-response curves to thromboxane-prostanoid 
receptor specific agonist U46619. Four curves were generated, one per treatment 
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incubation; CON, CC, Y and CC + Y. Each curve was characterized using three 
parameters: EC50, MAX and AUC. 
 
Vasomotor response to U46619 in young WKY 
The EC50 for all three drug incubation conditions (CC, Y, CC+Y) was 
significantly greater than that of the control (p<0.05; table 11). There was no significant 
difference between the separate incubation conditions. 
No significant differences in MAX or AUC were present between any conditions 
(table 11). 
 
HYPERTENSION RESPONSE TO U46619-INDUCED CONTRACTION 
Young WKY vs SHR 
Similar to the response observed in young WKY, young SHR showed 
significantly greater EC50 for all three incubation conditions compared to their respective 
control (p<0.05; table 11). There was no significant difference present between separate 
incubation conditions in young SHR. 
In the EC50 response of young WKY vs. SHR, the CON and CC incubation 
conditions were significantly lower in SHR compared to WKY (p<0.05; table 11). The 
SHR also developed significantly greater MAX tension in the separate CC, Y and 
combined CC+Y incubation conditions (p<0.05; table 11). AUC was significantly greater 
in SHR for only the combined Y incubation condition (p<0.05; table 11). 
In the EC50 response of old WKY and SHR, only the separate Y incubation 
condition was significantly different, with the EC50 being higher in WKY compared to 
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SHR (p<0.05; table 12). No significant differences in maximum developed tension or 
AUC were present for any incubation condition.  
 
AGING REPONSE TO U46619-INDUCED CONTRACTION 
WKY 
No significant differences in the EC50 response between old and young WKY 
were present. The MAX of the CON and separate CC incubation condition were both 
significantly greater in older WKY compared to young WKY (p<0.05; table 13). The 
AUC for the combined CC+Y incubation condition was significantly lower in the old 
WKY compared to the young WKY (p<0.05; table 13).  
 
SHR 
No significant differences were present between the EC50 response, MAX or AUC 
of young SHR compared to old SHR, with the exception of the AUC of the older SHR, 
which was significantly greater in the Y incubation condition (p<0.05; table 14). 
 
3-WAY ANOVA ANALYSIS OF CURVE PARAMETERS IN RESPONSE TO U46619-
INDUCED CONTRACTION 
EC50 
 3-Way ANOVA analysis revealed that EC50 in response to U46619-induced 
contraction was significantly affected by drug incubation and hypertension (p<0.05; table 
15). An interaction effect was also present between aging and hypertension (p<0.05; table 
15). 
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MAX 
 3-Way ANOVA analysis revealed that MAX tension in response to U46619-
induced contraction significantly was significantly affected by hypertension and aging 
(P<0.05; table 16). It also revealed that there was an interaction effect present between 
aging and hypertension (P<0.05; table 16). 
 
AUC 
 3-Way ANOVA analysis revealed that PE-induced contraction was significantly 
affected by incubation, hypertension and aging (P<0.05; table 17). There was also an 
interaction effect present between incubation and aging (P<0.05; table 17). 
 
RECEPTOR MEDIATED DIFFERENCES TO PHARMACOLOGICALLY-INDUCED 
CONTRACTION 
 In the CCA segments of all groups, the EC50 (nM) of PE was significantly lower 
than the sensitivity to U46619 (p<0.05; table 18, 19, 20, 21). This was confirmed when 
examining the change in the EC50 compared to the control for both the separate CC and Y 
conditions as well as the combined CC+Y condition (table 22). MAX was also affected 
by the contractile agonist used after incubation, with the response to PE-induced 
contraction having a much greater effect than U46619-induced contraction (table 23). 
Receptor-mediated differences were most pronounced in the young WKY group for both 
the EC50 and MAX responses to agonist-induced contraction (table 22, table 23) 
 
 35 
VASOMOTOR RESPONSE TO COMBINED AND SEPARATE AMPK AND HMG-CoA 
REDUCTASE INHIBITION 
The vasomotor constriction response to separate and combined AMPK and/or 
HMG-CoA inhibition was measured via dose-response curves to the α1-adrenergic 
receptor specific agonist PE. Four curves were generated: CON; CC; SIM; and, CC + 
SIM. Each curve was characterized using three parameters: half of the maximal effective 
concentration (EC50), maximum vasoconstriction (MAX) and the area under the curve 
(AUC) (table 24). 
The EC50 for all three drug incubation conditions (CC, SIM, CC+SIM) was 
significantly greater than that of the control (CON; p<0.05; table 24) with both the 
separate CC and Y conditions being significantly different to the combined CC+Y 
inhibition condition as well as being significant different to each other (p<0.05; table 24). 
The MAX was also measured, with the separate Y incubation condition and the 
combined CC+Y incubation condition being significantly lower than the control (p<0.05; 
table 24). There was no significant difference between the separate incubation conditions. 
The AUC for all three drug incubation conditions (CC, SIM, CC+SIM) was 
significantly lower than that of the control (CON; p<0.05; table 24) with both the 
separate CC and SIM conditions being significantly different to the combined CC+SIM 
inhibition condition as well as being significant different to each other (p<0.05; table 24). 
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Table 1: Study 1 WKY Rat characteristics 
 
Characteristic Young n Old n  p-value    
Age (weeks) 24.9±0.8 12 58.0±1.7 10  <0.01    
Body Mass (g) 395.0±5.3 12 445.8±6.9 10  <0.01    
Age expressed in weeks. Body mass expressed in grams. Young, animals classified as 
young; Old, animals classified as aged. P-value obtained by t-test for independent means. 
Data are presented as means ±!SEM. 
 
 
Table 2: Study 1 SHR Rat characteristics 
 
Characteristic Young n Old n p-value  
Age (weeks) 27.5±0.5 12 66.1±2.4 11 <0.01  
Body Mass (g) 405.4±4.2 12 420.8±6.6 11 <0.01  
Age expressed in weeks. Body mass expressed in grams. Young, animals classified as 
young; Old, animals classified as aged. P-value obtained by t-test for independent means. 
Data are presented as means ±!SEM.  
 
 
Table 3: Study 2 WKY characteristics 
 
Characteristic WKY rats n 
Age (weeks) 53.4±3.0 11 
Body Mass (g) 450.9±8.2 11 
Age expressed in weeks. Body mass expressed in grams. P-value obtained by t-test for 
independent means. Data are presented as means ±!SEM. 
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Figure 1: Vasoconstriction stimulated by phenylephrine (PE) in 2mm endothelium-
denuded (E-) young WKY (n=12) CCA segments incubated with no drug (CON), the 
AMPK inhibitor Compound C (CC; 20µM), the ROCK Y27632 (Y; 10-6.0 M) or a 
combination of Y27632 and CC (CC+Y; 20µM, 10-6.0 M) for 30 minutes. Contraction 
was stimulated following incubation using PE at concentrations from 10-9.0 to 10-4.5 M. 
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Figure 2: Vasoconstriction stimulated by phenylephrine (PE) in 2mm endothelium-
denuded (E-) young SHR (n=12) CCA segments incubated with no drug (CON), the 
AMPK inhibitor Compound C (CC; 20µM), the ROCK Y27632 (Y; 10-6.0 M) or a 
combination of Y27632 and CC (CC+Y; 20µM, 10-6.0 M) for 30 minutes. Contraction 
was stimulated following incubation using PE at concentrations from 10-9.0 to 10-4.5 M. 
  
Effect of AMPK and ROCK Inhibition (SHR - Young)
PE (Log M)
%
 o
f 6
0m
M
 K
C
l C
on
tr
ac
tio
n
-9.5 -9.0 -8.5 -8.0 -7.5 -7.0 -6.5 -6.0 -5.5 -5.0 -4.5
0
20
40
60
80
100
120
CON
CC
Y
CC+Y
 39 
Table 4: Strain comparison of PE curve parameters for young WKY and SHR 
 
PE - YOUNG EC50 (nM) MAX Tension (g) AUC (Arbitrary Units) 
 WKY SHR WKY SHR WKY SHR 
CON 21.7±3.2 14.5±1.1¥ 1.3±0.1 1.3±0.0 339.5±8.8 331.1±8.5 
CC 72.0±13.7*‡ 46.3±6.0*‡ 1.2±0.0‡ 1.3±0.0 245.6±8.0*‡ 248.2±8.8*‡ 
Y 78.7±8.9*‡ 67.1±8.4*‡ 1.1±0.0*‡ 1.3±0.1¥ 230.7±7.8*‡ 253.7±11.8*‡ 
CC+Y 234.4±42.3*§† 159.6±24.3*§† 0.9±0.1*§† 1.2±0.0*¥ 157.4±8.2*§† 184.2±5.6*§†¥ 
 
EC50 (nM), MAX (g) and AUC (arbitrary units) of young WKY (n=12) and SHR (n=12) CCA segments incubated with no drug 
(CON), the AMPK inhibitor Compound C (CC; 20µM), the ROCK inhibitor Y27632 (Y; 10-6 M) or a combination of Y27632 and CC 
for 30 minutes. Contraction was stimulated following incubation using PE at concentrations from 10-9.0 to 10-4.5 M. Data are presented 
as means ± SE. * P < 0.05 vs. CONTROL; § P < 0.05 vs. CC; † P < 0.05 vs. Y; ‡ P < 0.05 vs. CC+Y. ¥ P < 0.05 vs. WKY within 
treatment. 
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Figure 3: Vasoconstriction stimulated by phenylephrine (PE) in old WKY (n=10) CCA 
segments incubated with no drug (CON), the AMPK inhibitor Compound C (CC; 20µM), 
the ROCK inhibitor Y27632 (Y; 10-6.0 M) or a combination of Y27632 and CC (CC + Y) 
for 30 minutes. Contraction was stimulated following a 30-minute incubation using PE at 
concentrations from 10-9.0 to 10-4.5 M. 
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Figure 4: Vasoconstriction stimulated by phenylephrine (PE) in old SHR (n=11) CCA 
segments incubated with no drug (CON), the AMPK inhibitor Compound C (CC; 20µM), 
the ROCK inhibitor Y27632 (Y; 10-6.0 M) or a combination of Y27632 and CC (CC + Y) 
for 30 minutes. Contraction was stimulated following a 30-minute incubation using PE at 
concentrations from 10-9.0 to 10-4.5 M. 
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Table 5: Strain comparison of PE curve parameters for old WKY and SHR 
 
PE - OLD EC50 (nM) MAX Tension (g) AUC (Arbitrary Units) 
 WKY SHR WKY SHR WKY SHR 
CON 35.5±3.0 36.5±4.6 1.3±0.1 1.3±0.0 322.5±11.0 301.7±7.6 
CC 131.0±18.7*‡ 114.4±13.3*‡ 1.2±0.1 1.2±0.0*‡ 219.7±9.2*‡ 216.6±5.0*‡ 
Y 139.6±14.7*‡ 108.1±10.1* 1.2±0.1 1.3±0.0‡ 207.6±10.1*‡ 225.7±4.5*‡ 
CC+Y 240.6±15.7*§† 234.7±18.1*§† 1.1±0.1* 1.1±0.0*§† 157.0±6.8*§† 158.2±4.8*§† 
 
EC50 (nM), MAX (g) and AUC (arbitrary units) of old WKY (n=10) and SHR (n=11) CCA segments incubated with no drug (CON), 
the AMPK inhibitor Compound C (CC; 20µM), the ROCK inhibitor Y27632 (Y; 10-6.0 M) or a combination of Y27632 and CC for 30 
minutes. Contraction was stimulated following incubation using PE at concentrations from 10-9.0 to 10-4.5 M. Data are presented as 
means ± SE. * P < 0.05 vs. CONTROL; § P < 0.05 vs. CC; † P < 0.05 vs. Y; ‡ P < 0.05 vs. CC+Y. ¥ P < 0.05 vs. WKY within 
treatment. 
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Table 6: Age comparison of PE curve parameters for WKY 
 
PE - WKY EC50 (nM) MAX Tension (g) AUC (Arbitrary Units) 
 Young Old Young Old Young Old 
CON 21.7±3.2 35.5±3.0¥ 1.3±0.1 1.3±0.1 339.5±8.8 322.5±11.0 
CC 72.0±13.7*‡ 131.0±18.7*‡¥ 1.2±0.0‡ 1.2±0.1 245.6±8.0*‡ 219.7±9.2*‡ 
Y 78.7±8.9*‡ 139.6±14.7*‡¥ 1.1±0.0*‡ 1.2±0.1 230.7±7.8*‡ 207.6±10.1*‡ 
CC+Y 234.4±42.3*§† 240.6±15.7*§† 0.9±0.1*§† 1.1±0.1* 157.4±8.2*§† 157.0±6.8*§† 
 
EC50 (nM), MAX (g) and AUC (arbitrary units) of young (n=12) and old (n=10) WKY CCA segments incubated with no drug (CON), 
the AMPK inhibitor Compound C (CC; 20µM), the ROCK inhibitor Y27632 (Y; 10-6.0 M) or a combination of Y27632 and CC for 30 
minutes (n=11). Contraction was stimulated following incubation using PE at concentrations from 10-9.0 to 10-4.5 M. Data are presented 
as means ± SE. * P < 0.05 vs. CONTROL; § P < 0.05 vs. CC; † P < 0.05 vs. Y; ‡ P < 0.05 vs. CC+Y. ¥ P < 0.05 vs. Young within 
treatment. Note: for the sake of comparison, the data from the WKY young (table 4) and WKY old (table 5) is repeated for this table. 
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Table 7: Age comparison of PE curve parameters for SHR 
 
PE - SHR EC50 (nM) MAX Tension (g) AUC (Arbitrary Units) 
 Young Old Young Old Young Old 
CON 14.5±1.1 36.5±4.6¥ 1.3±0.0 1.3±0.0 331.1±8.5 301.7±7.6 
CC 46.3±6.0*‡ 114.4±13.3*‡¥ 1.3±0.0 1.2±0.0*‡ 248.2±8.8*‡ 216.6±5.0*‡ 
Y 67.1±8.4*‡ 108.1±10.1*¥ 1.3±0.1 1.3±0.0‡ 253.7±11.8*‡ 225.7±4.5*‡ 
CC+Y 159.6±24.3*§† 234.7±18.1*§†¥ 1.2±0.0* 1.1±0.0*§† 184.2±5.6*§†¥ 158.2±4.8*§† 
 
EC50 (nM), MAX (g) and AUC (arbitrary units) of young (n=12) and old (n=11) SHR CCA segments incubated with no drug (CON), 
the AMPK inhibitor Compound C (CC; 20µM), the ROCK inhibitor Y27632 (Y; 10-6.0 M) or a combination of Y27632 and CC for 30 
minutes (n=11). Contraction was stimulated following incubation using PE at concentrations from 10-9.0 to 10-4.5 M. Data are presented 
as means ± SE. * P < 0.05 vs. CONTROL; § P < 0.05 vs. CC; † P < 0.05 vs. Y; ‡ P < 0.05 vs. CC+Y. ¥ P < 0.05 vs. Young within 
treatment. Note: for the sake of comparison, data for the SHR young (table 4) and SHR old (table 5) is repeated for this table. 
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Table 8: 3-Way ANOVA table examining the EC50 response to PE-induced contraction 
 
EC50 response to PE 
Effect Sum of squares df Mean Square F value P value 
Incubation 777002.4 3 259000.8 89.1 0.000* 
Hypertension 19281.9 1 19281.9 6.6 0.110 
Age 75512.7 1 75512.7 26.0 0.000* 
Incubation x Hypertension 6412.8 3 2137.6 0.7 0.532 
Incubation x Age 11404.9 3 3801.6 1.3 0.274 
Age x Hypertension 2680.4 1 2680.4 0.9 0.338 
Incubation x HT x Age 12032.6 3 4010.9 1.4 0.251 
Error 430092.2 148 2906.0   
 
Effects are described as follows: Incubation refers to conditions isolated CCA segments were subject to in bath for 30 minutes prior to 
stimulation with PE; CON (no drug); CC (AMPK Inhibitor; 20 µM); Y (ROCK inhibitor; 10-6.0 M); CC + Y (combination of CC and 
Y at their respective separate concentrations). Hypertension refers to any differences resulting from strain (WKY vs. SHR). Age refers 
to any differences resulting from age (young vs. old). *P ≤ 0.05. 
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Table 9: 3-Way ANOVA table examining the MAX response to PE-induced contraction 
 
MAX response to PE 
Effect Sum of squares df Mean Square F value P value 
Incubation 1.1 3 0.4 15.7 0.000* 
Hypertension 0.2 1 0.2 10.3 0.011* 
Age 0.0 1 0.0 1.6 0.208 
Incubation x Hypertension 0.2 3 0.1 2.62 0.053 
Incubation x Age 0.0 3 0.0 0.1 0.974 
Age x Hypertension 0.2 1 0.2 8.2 0.005* 
Incubation x HT x Age 0.0 3 0.0 0.6 0.603 
Error 3.5 148 0.0   
 
Effects are described as follows: Incubation refers to conditions isolated CCA segments were subject to in bath for 30 minutes prior to 
stimulation with PE; CON (no drug); CC (AMPK Inhibitor; 20 µM); Y (ROCK inhibitor; 10-6.0 M); CC + Y (combination of CC and 
Y at their respective separate concentrations). Hypertension refers to any differences resulting from strain (WKY vs. SHR). Age refers 
to any differences resulting from age (young vs. old). *P ≤ 0.05. 
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Table 10: 3-Way ANOVA table examining the AUC response to PE-induced contraction 
 
AUC response to PE 
Effect Sum of squares df Mean Square F value P value 
Incubation 542584.7 3 180861.6 261.1 0.000* 
Hypertension 958.5 1 958.5 1.4 0.241 
Age 20830.4 1 20830.4 30.1 0.000* 
Incubation x Hypertension 6319.9 3 2106.6 3.0 0.031* 
Incubation x Age 1504.7 3 501.6 0.7 0.539 
Age x Hypertension 1627.0 1 1627.0 2.3 0.128 
Incubation x HT x Age 852.1 3 284.0 0.4 0.746 
Error 430092.2 148 2906.0   
 
Effects are described as follows: Incubation refers to conditions isolated CCA segments were subject to in bath for 30 minutes prior to 
stimulation with PE; CON (no drug); CC (AMPK Inhibitor; 20 µM); Y (ROCK inhibitor; 10-6.0 M); CC + Y (combination of CC and 
Y at their respective separate concentrations). Hypertension refers to any differences resulting from strain (WKY vs. SHR). Age refers 
to any differences resulting from age (young vs. old). *P ≤ 0.05. 
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Figure 5: Vasoconstriction stimulated by the TPr agonist U46619 in young WKY (n=10) 
CCA segments incubated with no drug (CON), the AMPK inhibitor Compound C (CC; 
20µM), the ROCK inhibitor Y27632 (Y; 10-6.0 M) or a combination of Y27632 and CC 
(CC + Y) for 30 minutes. Contraction was stimulated following a 30-minute incubation 
using U46619 at concentrations from 10-9.0 to 10-6.0 M. 
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Figure 6: Vasoconstriction stimulated by the TPr agonist U46619 in young SHR (n=11) 
CCA segments incubated with no drug (CON), the AMPK inhibitor Compound C (CC; 
20µM), the ROCK inhibitor Y27632 (Y; 10-6.0 M) or a combination of Y27632 and CC 
(CC + Y) for 30 minutes. Contraction was stimulated following a 30-minute incubation 
using U46619 at concentrations from 10-9.0 to 10-6.0 M. 
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Table 11: Strain response to U46619-induced contraction in young animals 
 
U46619 - YOUNG EC50 (nM) MAX Tension (g) AUC (Arbitrary Units) 
 WKY SHR WKY SHR WKY SHR 
CON 7.2±0.7 5.2±0.5¥ 1.5±0.1 1.6±0.1 243.1±9.7 274.3±5.1 
CC 11.1±1.7* 7.3±0.7*‡¥ 1.4±0.1 1.6±0.1¥ 219.0±5.3 236.0±6.9*‡ 
Y 10.7±1.4* 7.7±0.6* 1.5±0.1 1.7±0.0¥ 233.0±4.4 247.1±3.6*‡¥ 
CC+Y 13.8±1.9* 12.6±1.4*§ 1.4±0.1 1.6±0.0¥ 223.4±9.3 210.3±8.5*§† 
 
EC50 (nM), MAX (g) and AUC (arbitrary units) of young WKY (n=10) and SHR (n=11) CCA segments incubated with no drug 
(CON), the AMPK inhibitor Compound C (CC; 20µM), the ROCK inhibitor Y27632 (Y;10-6.0 M) or a combination of Y27632 and 
CC for 30 minutes. Contraction was stimulated following a 30-minute incubation using U46619 at concentrations from 10-9.0 to 10-6.0 
M. Data are presented as means ± SE. * P < 0.05 vs. CONTROL; § P < 0.05 vs. CC; † P < 0.05 vs. Y; ‡ P < 0.05 vs. CC+Y; ¥ P < 
0.05 vs. WKY within treatment.   
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Figure 7: Vasoconstriction stimulated by the TPr agonist U46619 in old WKY (n=13) 
CCA segments incubated with no drug (CON), the AMPK inhibitor Compound C (CC; 
20µM), the ROCK inhibitor Y27632 (Y; 10-6.0 M) or a combination of Y27632 and CC 
(CC + Y) for 30 minutes. Contraction was stimulated following a 30-minute incubation 
using U46619 at concentrations from 10-9.0 to 10-6.0 M. 
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Figure 8: Vasoconstriction stimulated by the TPr agonist U46619 in old SHR (n=10) 
CCA segments incubated with no drug (CON), the AMPK inhibitor Compound C (CC; 
20µM), the ROCK inhibitor Y27632 (Y; 10-6.0 M) or a combination of Y27632 and CC 
(CC + Y) for 30 minutes. Contraction was stimulated following a 30-minute incubation 
using U46619 at concentrations from 10-9.0 to 10-6.0 M. 
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Table 12: Strain response to U46619-induced contraction in old animals 
 
U46619 – OLD EC50 (nM) MAX Tension (g) AUC (Arbitrary Units) 
 WKY SHR WKY SHR WKY SHR 
CON 5.9±0.7 4.5±0.8 1.7±0.1 1.7±0.1 281.0±5.3 294.6±9.3 
CC 9.3±1.0*‡ 7.2±1.1 1.7±0.1† 1.7±0.1 240.5±5.9*‡ 251.1±8.1*‡ 
Y 10.1±1.1* 6.5±0.9‡¥ 1.6±0.1§ 1.6±0.1 240.8±6.1*‡ 264.0±6.0*‡¥ 
CC+Y 13.9±1.8*§ 11.3±1.7*† 1.6±0.1 1.6±0.1 208.3±5.6*§† 218.9±9.8*§† 
 
EC50 (nM), MAX (g) AUC (arbitrary units) of old WKY (n=13) and SHR (n=10) CCA segments incubated with no drug (CON), the 
AMPK inhibitor Compound C (CC; 20µM), the ROCK inhibitor Y27632 (10-6.0 M) or a combination of CC + Y for 30 minutes. 
Contraction was stimulated following a 30-minute incubation using U46619 at concentrations from 10-9.0 to 10-6.0 M. Data are 
presented as means ± SE. * P < 0.05 vs. CONTROL; § P < 0.05 vs. CC; † P < 0.05 vs. Y; ‡ P < 0.05 vs. CC+Y; ¥ P < 0.05 vs. WKY 
within treatment. 
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Table 13: Age response to U46619-induced contraction in WKY animals 
 
U46619 - WKY EC50 (nM) MAX Tension (g) AUC (Arbitrary Units) 
 Young Old Young Old Young Old 
CON 7.2±0.7 5.9±0.7 1.5±0.1 1.7±0.1 243.1±9.7 281.0±5.3 
CC 11.1±1.7* 9.3±1.0*‡ 1.4±0.1 1.7±0.1† 219.0±5.3 240.5±5.9*‡ 
Y 10.7±1.4* 10.1±1.1* 1.5±0.1 1.6±0.1§ 233.0±4.4 240.8±6.1*‡ 
CC+Y 13.8±1.9* 13.9±1.8*§ 1.4±0.1 1.6±0.1 223.4±9.3 208.3±5.6*§† 
 
EC50 (nM), MAX (g) and AUC (arbitrary units) of young (n=12) and old (n=10) WKY CCA segments incubated with no drug (CON), 
the AMPK inhibitor Compound C (CC; 20µM), the ROCK inhibitor Y27632 (Y; 10-6.0 M) or a combination of Y27632 and CC for 30 
minutes (n=11). Contraction was stimulated following incubation using U46619 at concentrations from 10-9.0 to 10-6.0 M. Data are 
presented as means ± SE. * P < 0.05 vs. CONTROL; § P < 0.05 vs. CC; † P < 0.05 vs. Y; ‡ P < 0.05 vs. CC+Y. ¥ P < 0.05 vs. Young 
within treatment. Note: for the sake of comparison, data for the WKY young (table 11) and WKY old (table 12) is repeated for this 
table. 
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Table 14: Age response to U46619-induced contraction in SHR animals 
 
U46619 - SHR EC50 (nM) MAX Tension (g) AUC (Arbitrary Units) 
 Young Old Young Old Young Old 
CON 5.2±0.5 4.5±0.8 1.6±0.1 1.7±0.1 274.3±5.1 294.6±9.3 
CC 7.3±0.7*‡ 7.2±1.1 1.6±0.1 1.7±0.1 236.0±6.9*‡ 251.1±8.1*‡ 
Y 7.7±0.6* 6.5±0.9‡ 1.7±0.0 1.6±0.1 247.1±3.6*‡ 264.0±6.0*‡¥` 
CC+Y 12.6±1.4*§ 11.3±1.7*† 1.6±0.0 1.6±0.1 210.3±8.5*§† 218.9±9.6*§† 
 
EC50 (nM), MAX (g) and AUC (arbitrary units) of young (n=12) and old (n=11) SHR CCA segments incubated with no drug (CON), 
the AMPK inhibitor Compound C (CC; 20µM), the ROCK inhibitor Y27632 (Y; 10-6.0 M) or a combination of Y27632 and CC for 30 
minutes (n=11). Contraction was stimulated following incubation using U46619 at concentrations from 10-9.0 to 10-6.0 M. Data are 
presented as means ± SE. * P < 0.05 vs. CONTROL; § P < 0.05 vs. CC; † P < 0.05 vs. Y; ‡ P < 0.05 vs. CC+Y. ¥ P < 0.05 vs. Young 
within treatment. Note: for the sake of comparison, data for the SHR young (table 11) and SHR old (table 12) is repeated for this table. 
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Table 15: 3-Way ANOVA table examining the EC50 response to U46619-induced contraction 
 
EC50 response to U46619 
Effect Sum of squares df Mean Square F value P value 
Incubation 921.7 3 307.2 28.8 0.000* 
Hypertension 73.2 1 73.2 6.9 0.010* 
Age 4.4 1 4.4 0.4 0.524 
Incubation x Hypertension 17.7 3 5.9 0.6 0.648 
Incubation x Age 13.8 3 4.6 0.4 0.731 
Age x Hypertension 44.4 1 44.4 4.2 0.043* 
Incubation x HT x Age 8.8 3 12.9 1.2 0.308 
Error 1580.4 148 10.7   
 
Effects are described as follows: Incubation refers to conditions isolated CCA segments were subject to in bath for 30 minutes prior to 
stimulation with U46619; CON (no drug); CC (AMPK Inhibitor; 20 µM); Y (ROCK inhibitor; 10-6.0 M); CC + Y (combination of CC 
and Y at their respective separate concentrations). Hypertension refers to any differences resulting from strain (WKY vs. SHR). Age 
refers to any differences resulting from age (young vs. old). *P ≤ 0.05. 
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Table 16: 3-Way ANOVA table examining the MAX response to U46619-induced contraction 
 
MAX response to U46619 
Effect Sum of squares df Mean Square F value P value 
Incubation 0.1 3 0.0 0.8 0.493 
Hypertension 0.3 1 0.3 7.3 0.008* 
Age 0.3 1 0.4 8.7 0.004* 
Incubation x Hypertension 0.0 3 0.0 0.1 0.975 
Incubation x Age 0.2 3 0.1 1.3 0.291 
Age x Hypertension 0.3 1 0.3 6.5 0.012* 
Incubation x HT x Age 0.0 3 0.0 0.3 0.808 
Error 6.0 148 0.0   
 
Effects are described as follows: Incubation refers to conditions isolated CCA segments were subject to in bath for 30 minutes prior to 
stimulation with U46619; CON (no drug); CC (AMPK Inhibitor; 20 µM); Y (ROCK inhibitor; 10-6.0 M); CC + Y (combination of CC 
and Y at their respective separate concentrations). Hypertension refers to any differences resulting from strain (WKY vs. SHR). Age 
refers to any differences resulting from age (young vs. old). *P ≤ 0.05. 
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Table 17: 3-Way ANOVA table examining the AUC response to U46619-induced contraction 
 
AUC response to U46619 
Effect Sum of squares df Mean Square F value P value 
Incubation 70305.4 3 23435.1 46.9 0.000* 
Hypertension 7087.4 1 7087.4 14.2 0.000* 
Age 7910.7 1 7910.7 15.8 0.000* 
Incubation x Hypertension 3242.8 3 1080.9 2.2 0.095 
Incubation x Age 5492.3 3 1830.8 3.7 0.014* 
Age x Hypertension 48.6 1 48.6 0.1 0.756 
Incubation x HT x Age 2460.6 3 820.2 1.6 0.182 
Error 1580.4 148 10.7   
 
Effects are described as follows: Incubation refers to conditions isolated CCA segments were subject to in bath for 30 minutes prior to 
stimulation with U46619; CON (no drug); CC (AMPK Inhibitor; 20 µM); Y (ROCK inhibitor; 10-6.0 M); CC + Y (combination of CC 
and Y at their respective separate concentrations). Hypertension refers to any differences resulting from strain (WKY vs. SHR). Age 
refers to any differences resulting from age (young vs. old). *P ≤ 0.05. 
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Table 18: Receptor mediated differences in the curve parameters of young WKY 
 
Young WKY EC50 (nM) MAX Tension (g) AUC (Arbitrary Units) 
 PE U46619 PE U46619 PE U46619 
CON 21.7±3.2 7.2±0.7 1.3±0.1 1.4±0.1 339.5±8.8 243.1±9.7 
CC 72.0±13.7*‡ 11.1±1.7* 1.2±0.0‡ 1.4±0.1 245.6±8.0*‡ 219.0±5.3 
Y 78.7±8.9*‡ 10.7±1.4* 1.1±0.0*‡ 1.5±0.1 230.7±7.8*‡ 233.0±4.4 
CC+Y 234.4±42.3*§† 13.8±1.9* 0.9±0.1*§† 1.4±0.1 157.4±8.2*§† 223.4±9.3 
 
EC50 (nM), MAX (g) and AUC (arbitrary units) of young WKY CCA segments incubated with no drug (CON), the AMPK inhibitor 
Compound C (CC; 20µM), the Rho-kinase inhibitor Y27632 (Y; 10-6.0 M) or a combination of Y27632 and CC (CC+Y) for 30 
minutes. CCA segments were subject to two contractile agonists; PE and U46619). Data are presented as means ± SE. * P < 0.05 vs. 
CONTROL; § P < 0.05 vs. CC; † P < 0.05 vs. Y; ‡ P < 0.05 vs. CC+Y. Note: for the sake of comparison, data for the WKY young PE 
responses (table 4) and WKY young U46619 responses (table 11) is repeated for this table. 
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Table 19: Receptor mediated differences in the curve parameters of young SHR 
 
Young SHR EC50 (nM) MAX Tension (g) AUC (Arbitrary Units) 
 PE U46619 PE U46619 PE U46619 
CON 14.5±1.1 5.2±0.5 1.3±0.0 1.6±0.1 331.1±8.5 274.3±5.1 
CC 46.3±6.0*‡ 7.3±0.7*‡ 1.3±0.0 1.6±0.1 248.2±8.8*‡ 236.0±6.9*‡ 
Y 67.1±8.4*‡ 7.7±0.6* 1.3±0.1 1.7±0.0 253.7±11.8*‡ 247.1±3.6*‡ 
CC+Y 159.6±24.3*§† 12.6±1.4*§ 1.2±0.0* 1.6±0.0 184.2±5.6*§† 210.3±8.5*§† 
 
EC50 (nM), MAX (g) and AUC (arbitrary units) of young SHR CCA segments incubated with no drug (CON), the AMPK inhibitor 
Compound C (CC; 20µM), the Rho-kinase inhibitor Y27632 (10-6.0 M) or a combination of Y27632 and CC for 30 minutes. CCA 
segments were subject to two contractile agonists; PE and U46619). Data are presented as means ± SE. * P < 0.05 vs. CONTROL; § P 
< 0.05 vs. CC; † P < 0.05 vs. Y; ‡ P < 0.05 vs. CC+Y. Note: for the sake of comparison, data for the SHR young PE responses (table 
4) and SHR young U46619 responses (table 11) is repeated for this table. 
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Table 20: Receptor mediated differences in the curve parameters of old WKY 
OLD WKY EC50 (nM) MAX Tension (g) AUC (Arbitrary Units) 
 PE U46619 PE U46619 PE U46619 
CON 35.5±3.0 5.9±0.7 1.3±0.1 1.7±0.1¥ 322.5±11.0 281.0±5.3 
CC 131.0±18.7*‡ 9.3±1.0*‡ 1.2±0.1 1.7±0.1†¥ 219.7±9.2*‡ 240.5±5.9*‡ 
Y 139.6±14.7*‡ 10.1±1.1* 1.2±0.1 1.6±0.1§ 207.6±10.1*‡ 240.8±6.1*‡ 
CC+Y 240.6±15.7*§† 13.9±1.8*§ 1.1±0.1* 1.6±0.1 157.0±6.8*§† 208.3±5.6*§† 
 
EC50 (nM), MAX(g) and AUC (arbitrary units) of old WKY CCA segments incubated with no drug (CON), the AMPK inhibitor 
Compound C (CC; 20µM), the Rho-kinase inhibitor Y27632 (10-6.0 M) or a combination of Y27632 and CC for 30 minutes. CCA 
segments were subject to two contractile agonists; PE and U46619). Data are presented as means ± SE. * P < 0.05 vs. CONTROL; § P 
< 0.05 vs. CC; † P < 0.05 vs. Y; ‡ P < 0.05 vs. CC+Y. Note: for the sake of comparison, data for the WKY old PE responses (table 5) 
and WKY old U46619 responses (table 12) is repeated for this table. 
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Table 21: Receptor mediated differences in the curve parameters of old SHR 
Old SHR EC50 (nM) MAX Tension (g) AUC (Arbitrary Units) 
 PE U46619 PE U46619 PE U46619 
CON 36.5±4.6 4.5±0.8 1.3±0.0 1.7±0.1 294.6±9.3 301.7±7.6 
CC 114.4±13.3*‡ 7.2±1.1 1.2±0.0*‡ 1.7±0.1 251.6±8.1*‡ 216.6±5.0*‡ 
Y 108.1±10.1* 6.5±0.9‡ 1.3±0.0‡ 1.6±0.1 264.0±6.0*‡ 225.7±4.5*‡ 
CC+Y 234.7±18.1*§† 11.3±1.7*† 1.1±0.0*§† 1.6±0.1 218.9±9.6*§† 158.2±4.8*§† 
 
EC50 (nM), MAX (g) and AUC (arbitrary units) of old SHR CCA segments incubated with no drug (CON), the AMPK inhibitor 
Compound C (CC; 20µM), the Rho-kinase inhibitor Y27632 (10-6.0 M) or a combination of Y27632 and CC for 30 minutes. CCA 
segments were subject to two contractile agonists; PE and U46619). Data are presented as means ± SE. * P < 0.05 vs. CONTROL; § P 
< 0.05 vs. CC; † P < 0.05 vs. Y; ‡ P < 0.05 vs. CC+Y. Note: for the sake of comparison, data for the SHR old PE responses (table 5) 
and SHR old U46619 responses (table 12) is repeated for this table. 
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Table 22: Changes in EC50 in response to agonist induced contraction for all groups 
 
Increase in EC50 vs. CON (fold difference) 
 WKY Young SHR Young WKY Old SHR Old 
 PE U46619 PE U46619 PE U46619 PE U46619 
CC 3.4±0.3*‡ 1.6±0.1* 3.2±0.3*‡ 1.4±0.1*‡ 3.8±0.6*‡ 1.6±0.1*‡ 3.5±0.4*‡ 1.7±0.1 
Y 4.0±0.4*‡ 1.5±0.1* 4.9±0.6*‡ 1.5±0.1* 4.0±0.3*‡ 1.8±0.2* 3.1±0.2* 1.5±0.1‡ 
CC+Y 13.0±3.5*§† 1.9±0.1* 11.5±1.9*§† 2.4±0.1*§ 7.3±0.9*§† 2.4±0.2*§ 7.6±1.2*§† 2.6±0.2*‡ 
 
Shift in EC50 for ALL groups (WKY/SHR; young/old). Response to incubation with the AMPK inhibitor Compound C (CC; 20µM), 
the Rho-kinase inhibitor Y27632 (Y; 10-6.0 M) or a combination of CC and Y for 30 minutes. CCA segments were subject to two 
contractile agonists; PE and U46619). Changes are expressed as fold increase vs. CON. * P < 0.05 vs. CONTROL; § P < 0.05 vs. CC; 
† P < 0.05 vs. Y; ‡ P < 0.05 vs. CC+Y. Data are presented as means ± SE. 
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Table 23: Changes in MAX response to agonist induced contraction in all groups 
Change in MAX tension vs. CON (% grams) 
 WKY Young SHR Young WKY Old SHR Old 
 PE U46619 PE U46619 PE U46619 PE U46619 
CC 9.3±3.4‡ 1.0±4.5 3.4±3.7 -2.7±3.8 7.7±3.9 -6.2±4.8† 8.3±3.5*‡ -1.8±3.2 
Y 14.6±4.0*‡ 0.0±4.4 0.4±2.8 -4.8±3.1 10.7±4.2 3.7±4.5§ 2.2±2.9‡ 0.2±4.0 
CC+Y 26.2±4.1*§† 1.3±3.2 9.6±2.2* -0.7±2.5 20.1±4.6* 4.5±3.8 16.8±2.5*§† 2.4±3.7 
 
Changes in MAX for all groups. Response to incubation with the AMPK inhibitor Compound C (CC; 20µM), the Rho-kinase inhibitor 
Y27632 (Y; 10-6.0 M) or a combination of CC and Y for 30 minutes. CCA segments were subject to two contractile agonists; PE and 
U46619). Changes are expressed as % magnitude (grams) of CON. * P < 0.05 vs. CONTROL; § P < 0.05 vs. CC; † P < 0.05 vs. Y; ‡ 
P < 0.05 vs. CC+Y. Data are presented as means ± SE. 
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Figure 9: Vasoconstriction stimulated by phenylephrine (PE) in old WKY (n=11) CCA 
segments incubated with no drug (CON), the AMPK inhibitor Compound C (CC; 20µM), 
the HMG-CoA reductase inhibitor Simvastatin (SIM; 5 µM) or a combination of CC + 
SIM for 30 minutes. Contraction was stimulated following a 45-minute incubation using 
PE at concentrations from 10-9.0 to 10-4.5 M. 
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Table 24: Curve parameters for WKY response to HMG-CoA reductase inhibition 
 
WKY EC50 (nM) MAX Tension (g) AUC (Arbitrary Units) 
CON 24.8±2.2 1.4±0.0 322.3±7.4 
CC 85.9±12.0*†‡ 1.2±0.0* 224.5±8.4*†‡ 
SIM 49.3±4.4*§‡ 1.3±0.1 273.0±8.4*†‡ 
CC+SIM 134.5±13.0*§† 1.2±0.1* 187.8±9.3*§† 
 
EC50 (nM), MAX(g) and AUC (arbitrary units) of old WKY (n=11) CCA segments incubated with no drug (CON), the AMPK 
inhibitor Compound C (CC; 20µM), the HMG-CoA reductase inhibitor Simvastatin (SIM; 5µM) or a combination of CC + SIM for 45 
minutes. Contraction was stimulated following incubation using PE at concentrations from 10-9.0 to 10-4.5 M. Data are presented as 
means ± SE. * P < 0.05 vs. CONTROL; § P < 0.05 vs. CC; † P < 0.05 vs. SIM; ‡ P < 0.05 vs. CC+Y. 
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DISCUSSION 
With its involvement in the regulation of VSM contraction yet to be fully 
characterized, the potential role of AMPK activity in smooth muscle contraction is a 
relatively new and emerging topic in cardiovascular research. The global objective of this 
thesis was to examine the subcellular mechanisms regulating vascular smooth muscle 
contraction, particularly the possible interaction between two vascular smooth muscle 
signaling pathways involving AMPK and ROCK.  This was examined under normal 
conditions, and in both aging and hypertensive models in endothelium-denuded CCA 
segments. The main findings of this thesis were: 
1. A basal level of AMPK activation is necessary in the normal VSM response to 
PE-induced contraction. 
2. Combined and separate AMPK and ROCK inhibition significantly increased the 
EC50 and decreased the maximum tension developed in the contractile response to 
PE and, to a lesser extent, U46619. 
3. The contribution of TPr-agonist activity is comparatively less affected by AMPK 
and/or ROCK inhibition when contrasted to PE-induced contraction. 
4. VSM is more sensitive to TPr stimulation compared to alpha-adrenergic 
stimulation, indicated by the EC50 comparisons made between the two agonists. 
5. Hypertension and aging do significantly affect VSM smooth muscle contraction 
by causing a slight increase in EC50, with greatest difference in curve parameter 
measurements present in the old SHR.  
6. The HMG-CoA reductase inhibitor Simvastatin acts in a similar fashion to 
Y27632 in PE-induced contractile responses in isolated WKY CCA. 
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AMPK inhibition inhibits contraction in isolated WKY CCA 
 After its identification as a kinase of HMG-CoA reductase16, AMPK quickly 
became the target of metabolic research. Characterization of AMPK in vascular research 
has been vague, as little is known about the role AMPK has in regulating vascular tone, 
specifically the balance between the phosphorylation of the regulatory contractile 
proteins MLCK and MLCP. The current study evaluated the role of AMPK in regulating 
pharmacologically induced contraction of isolated WKY CCA segments.  
  In previous work examining the role of AMPK activation in vasorelaxion, 
activation of AMPK in pre-contracted isolated vessels has been shown to induce 
vasodilation in both an endothelium –dependent and –independent fashion30. This 
activation effect of AMPK is voided by compound C and thusly; one would expect 
AMPK inhibition to blunt the ability of VSM to relax, increasing the relative response to 
agonist stimulation and thus increase contraction. We anticipated a change that would 
favour a decreased EC50 and an increased maximum developed tension at the same 
agonist concentration because of the inhibited ability for AMPK to induce vasodilation. 
However, this is not the case. Our work clearly shows that, in young WKY CCA 
segments, AMPK inhibition via the AMPK inhibitor Compound C (CC; 20 µM) proved 
effective at inhibiting the contractile response to pharmacologically induced contraction 
(table 4). 30-minute incubation with CC caused a marked increase in the EC50 of both 
PE-induced (~3 fold increase) and U46619-induced (~1.5 fold increase) VSM contraction 
(table 22). Increased EC50 in response to CC incubation was observed in all groups across 
both studies with the exception of the old SHR animals exposed to U46619 (table 14), 
where contraction was not significantly affected by AMPK inhibition via CC. This 
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increase in EC50 in the presence of CC alone indicates that AMPK contributes during the 
normal contractile response, and is thus involved in eliciting contraction in VSM. More 
investigation is required to determine where AMPK is acting in regulation of VSM tone. 
The suppression of the VSM contraction via incubation with CC could be the 
consequence of modulation of the MLCK activity of the VSM. By revisiting the original 
work on AMPK and its identification as an “energy-sensing” kinase82, it seems likely that 
AMPK is acting on specific components of the cell signaling pathways involved in 
energy management during VSM contraction. With known effects on regulatory MLC 
phosphorylation, AMPK inhibition could play a role in altering MLCK phosphorylation, 
possibly via decreasing calcium sensitivity of MLCK. This could indicate that AMPK 
activity is necessary for MLCK activity to initiate VSM contraction though more work is 
needed to verify if this mechanism can account for the reduction in contractile function of 
VSM in response to AMPK inhibition. 
 
ROCK inhibition inhibits contraction in isolated WKY CCA 
 The RhoA/ROCK pathway is a major signaling pathway responsible for the 
management of MLCP activity and thus, the management of vascular tone11. Recent work 
has shown that in VSM, ROCK activity could be linked to AMPK activity through 
modulation of Rho-GEFs13. With ROCK partially inhibited via Y27632, it is expected 
that U46619 would not induce a significant contractile response. Contrary to our 
anticipated results, inhibition of ROCK via Y27632 caused a significant increase in the 
EC50 in all WKY CCA segments. This effect was seen during ROCK inhibition in PE-
induced contraction and was also present, to a much lesser extent, during U46619-
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induced contraction. Maximum developed tension was also significantly lower in young 
and old WKY compared to their SHR counterparts, but only for vessels exposed to PE-
induced contraction. This was an unexpected result as U46619-induced contraction is 
initiated via thromboxane-prostanoid GPCR activity, leading to RhoA/ROCK activation 
and thus MLCP inhibition. This also suggests that the TPr receptor pathway responsible 
for initiating contraction is affected to a much lesser degree than the alpha-adrenergic 
GPCR contractile pathway during by AMPK and/or ROCK inhibition. This pattern is 
evident during the increased EC50 response to AMPK and/or ROCK inhibition across all 
groups (table 22).  
Surprisingly, there was little significant difference between old SHR and WKY 
groups exposed to U46619 treatment. Increased basal ROCK activity is a characteristic of 
hypertension and aging, and thus the old SHR are most likely to exhibit the highest 
amount of basal ROCK activity when compared to the other animal groups. This higher 
proportionate basal ROCK activation in the old SHR could account for the lack of 
significance in the old SHR exposed to U46619-induced contraction (table 12), even in 
the presence of the ROCK inhibitor Y27632. 
 
Combined AMPK and ROCK inhibition in amplifies the inhibition of contraction in 
isolated WKY CCA 
 With evidence supporting the activity of AMPK and ROCK in smooth muscle 
contraction13, this thesis aimed to examine and evaluate the contribution that AMPK and 
ROCK would have, either separately or in combination, during VSM contraction. If the 
effect of AMPK on VSM contraction is ROCK-dependent during VSM contraction, then 
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AMPK and ROCK inhibition in combination should not result in any differences 
compared to separate/individual AMPK or ROCK inhibition conditions. This thesis 
showed that separate AMPK or ROCK inhibition significantly increased the EC50 of PE-
induced contraction. However, the combined AMPK and ROCK inhibition further 
amplified the magnitude of this contraction inhibition when paired with each other. This 
additive effect was greatest in the WKY groups exposed to PE-induced contraction, with 
a similar pattern of response in the U46619-induced contraction group, but to a much 
lesser extent.  
 These results provoke an interesting scenario, one where the separate incubation 
conditions alter contraction response, but also where combination of the two further 
increases the magnitude of that response. This indicates that AMPK and ROCK activity 
likely modulates PE-induced contraction in one of two ways: either independently of one 
another, or, in a way that they are both partially affecting the same process that regulates 
contraction. This, in concert with minimal decreases in maximum developed tension, is 
contradicted by the relatively minimal shift in the EC50 in CCA segments treated with the 
TPr agonist U46619. Comparison of the fold increase in EC50 (table 22) provides a 
strong case, depicting the huge difference in sensitivity to the specific vascular agonists 
PE and U46619, with AMPK and/or ROCK inhibition having a much greater blunting 
effect on PE-induced contraction. In the young WKY response to AMPK inhibition, we 
observed ~3.4 fold increase in the EC50 for PE compared to only ~1.6 fold increase for 
U46619. The EC50 was further increased when AMPK and ROCK inhibition were 
combined for both conditions, with PE requiring a ~13 fold increase in EC50 (vs. CON) 
while U46619 only required ~2 fold increase (vs. CON)(table 22). This is a clear 
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indication of the receptor-mediated differences present in AMPK activity during agonist-
induced VSM contraction. 
 
Receptor mediated differences are present in the role of AMPK in VSM contraction 
 Significant effects of AMPK inhibition were observed in the three curve 
parameters from the PE-induced contraction studies compared to the minimal differences 
found in U46619-induced contraction. The increased EC50 for PE-induced contraction 
were greater, on average, than the shifts in EC50 for U46619 for the CC, Y and CC+Y 
incubation conditions (table 22), with the young animals having the greatest differences 
compared to the old animals. Hypertension was less effective at modulating receptor 
mediated differences compared to age (table 4/5), with aging having a greater blunting 
response on increasing EC50 (table 6). The contribution of AMPK and ROCK activity was 
minimal in U46619 as no significant changes in maximum developed tension were 
present for any group in any condition, with the exception of the CC incubation condition 
in the old WKY being slightly higher than that of the Y27632 incubation condition. This 
is significant for two reasons: 1) this demonstrates that thromboxane-prostanoid receptor 
signaling pathways are relatively unaffected by AMPK inhibition during agoinst-induced 
contraction and 2) that this TPr-specific effect is not modulated by the pathologies of age 
and hypertension in VSM alone.  
 These findings also confirm that ROCK activity is involved in GPCR alpha-
adrenergic induced-contraction. PE-induced contraction likely causes an influx of 
calcium, leading to the formation of the Ca-CaM complex, and thus contraction. We 
know AMPK inhibition reduces the magnitude of contraction, and contraction is 
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dependent on calcium influx, whether it be from outside the VSM or from internal 
calcium stores. It is likely that AMPK activity is necessary for the release of calcium 
from intracellular stores or that it is necessary for initiating the influx of calcium from 
outside of the VSM. By inhibiting AMPK activity, the kinase would be rendered inactive 
and thus unable to phosphorylate intermediates in the calcium signaling pathways that are 
required for VSM contraction. Further study is required to elucidate the specific 
mechanisms of AMPK activity in alpha-adrenergic induced VSM contraction. 
 
Hypertension  
Significant differences were present in both the young and old groups when 
examining hypertension effects on PE-induced contraction, with the greatest EC50 effect 
present in the young animals, with SHR controls having a greater EC50 than their WKY 
counterparts (table 4/5). Though the young SHR also showed reduced maximum 
developed tension within their group, they also had a slightly greater maximum 
developed tension compared to the age-matched WKY (table 4/5). With the exception of 
the AUC for Y27632 incubation in the old SHR, there were no other significant strain 
differences present between old WKY and SHR, suggesting the vascular response to 
contraction in hypertension is unaffected by AMPK and/or ROCK inhibition. 
 WKY exposed to the TPr agonist U46619 showed little significant difference in 
EC50 to their SHR counterparts. A slight reduction in the EC50 for the CON and CC 
incubations in young animals (table 11), and the Y incubation in old SHR (table 12) was 
present with the young SHR having significantly higher maximum developed tension 
compared to young WKY as well, a result in accordance with previous literature. SHR 
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rats are known to have more active RhoA signaling7,76 compared to age-matched WKY 
and are thus more sensitive to TPr stimulation, possibly explaining why the maximum 
developed tension was greater in the young SHR group compared to the young WKY. 
 The magnitude of these effects on the EC50 was relatively minor, indicating that 
the inhibition of AMPK in VSM alone is likely not involved in the pathological 
deficiencies associated with hypertension. This result in our hypertensive model seems 
logical because several attributes associated with hypertension are often associated with 
endothelial dysfunction. Such attributes include increased prostanoid production, reduced 
eNOS activity, increased inflammatory cytokines and increased EDCFs76,83,84. With the 
removal of the endothelium, confounding factors associated with hypertension were 
eliminated and thus could not contribute to any differences observed in our hypertensive 
model. More study would be required, possibly with an intact endothelium, to thoroughly 
examine the balance of these signaling mechanisms and their role in hypertension. 
 
Aging 
 Aging is associated with several mechanical and cellular changes48,49 that alter 
cardiovascular function in both WKY and SHR60,68. Our results regarding the aging effect 
are very similar to changes observed in the hypertensive state, with an increased EC50 in 
the older animals compared to the younger animals, within strain. This was only true of 
animals exposed to PE-induced contraction, indicating that age augmented the receptor-
mediated differences present in the U46619 response. This could be the result of changes 
in receptor-density associated with aging, with the potential for proportionately more 
alpha-adrenergic receptors in older animals compared to younger animals, resulting in a 
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more robust contractile response to PE. This is confirmed by the fact that, with the 
exception of the CC+Y incubation in old SHR compared to the young SHR, there were 
no significant differences in maximum developed tension. With an exclusive shift in the 
EC50 occurring, we know that aging alters the sensitivity of isolated CCA vessels to 
alpha-adrenergic stimulation, with older animals requiring a higher concentration of the 
agonist to elicit the same amount of absolute tension (contractile ability is not altered, 
only receptor sensitivity). 
 U46619-induced contraction did not affect the aging SHR EC50 or MAX response 
and only showed slight significant differences between young and old WKY in the CON 
and CC incubation conditions for maximum developed tension. This indicates that, in 
aging, TPr-mediated contraction in VSM is comparative unaffected when compared to 
the differences exhibited in PE-induced contraction. 
 
Statins 
 One of the most novel findings of this thesis was the discovery that HMG-CoA 
reductase inhibition via Simvastatin modulates alpha-adrenergic induced VSM 
contraction. Statins have been shown to alter a variety of cellular signaling mechanisms 
including ROS handling, reduced inflammatory signaling and anti-thrombotic effects52-54. 
It is also demonstrated that statins can inhibit potassium channel activity in porcine 
coronary arteries, leading to impaired vasorelaxation85. In isolated WKY CCA segments, 
it is possible that Simvastatin has a similar effect on Ca2+ channels, and possibly the 
RhoA/ROCK mediation of alpha-adrenergic induced contraction. Our results show that 
45-minute incubation with simvastatin (5µM), alone, significantly lowers the EC50 and 
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maximum developed tension of denuded isolated WKY CCA segments. In combination 
with the AMPK inhibitor CC, the magnitude of this reduction is amplified. Simvastatin 
effects showed several parallels with the ROCK inhibitor responses during PE-induced 
contraction with respect to effects on curve parameters. Thus, simvastatin has a sort of 
“Y27632 mimetic” effect. In age-matched WKY CCA segments, both Y27632 and 
Simvastatin incubation led to comparable increases in the EC50, as well as decreases in 
the maximum developed tension produced by PE-induced contraction (Table 5 vs. Table 
28). This also confirms that signaling mechanisms involving the manipulation of HMG-
CoA reductase activity in VSM can alter the manner in which VSM contraction is 
generated. However, it should be noted that statins have been studied to have a variety of 
effects in other types of tissue found outside of the vasculature. These observable effects 
in VSM could be pleiotropic in nature and should not be attributed to HMG-CoA 
reductase inhibition alone. Further investigation will be required to uncover how 
significant the role of VSM HMG-CoA reductase activity is during the maintenance and 
regulation of vascular tone.  
 
Limitations 
 Animal availability sometimes restricted our ability to use animals of appropriate 
age. In addition to availability, it was difficult to determine an appropriate age for our 
“aging” criteria since most rats live to an age of about 2 years (~100 weeks) though some 
of our rats exhibited early-onset pathological conditions associated with aging.  
 Biochemical assessment of the AMPK, ROCK and HMG-CoA reductase 
activation state would have been ideal in order to characterize their effect during VSM 
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contraction in more detail. Early attempts at Western blotting for these proteins in both 
their normal and phosphorylated state yielded blots insufficient for use in this document.  
 Use of arterial segments with an intact endothelium could have greatly augmented 
the data set presented in this document while concurrently expanding on the 
characterization of AMPK in regulating vascular tone. However, preparations devoid of 
the endothelium were a clearer way of distinguishing how AMPK activity affects 
contraction at the level of the VSM alone. 
 
Conclusions 
In summary, AMPK activity is involved and necessary for normal alpha-
adrenergic induced contraction. Inhibition of this enzyme, both separately or combined 
with ROCK inhibition, significantly increases the EC50 and maximum developed tension 
of isolated CCA segments in both WKY and SHR, indicating a reduced sensitivity to the 
alpha-adrenergic agonist PE in a dose-dependent fashion. Moreover, this effect is almost 
exclusive to alpha-adrenergic signaling, with isolated CCA segments in the same 
incubation conditions eliciting a much lower degree of responsiveness to the TPr agonist 
U46619. HMG-CoA reductase inhibition via Simvastatin also modulates alpha-
adrenergic induced contraction by acting as a Y27632 mimetic. More research will be 
required to identify the specific intracellular signaling mechanisms that account for these 
responses to AMPK inhibition in VSM and whether or not manipulation of these 
functional characteristics could prove beneficial in specific diseased states such as aging 
and hypertension. 
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APPENDIX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplement 1: Pilot work examining the effect of sodium salicylate (SS) and AMPK 
inhibition on relaxation in isolated WKY CCA segments (E+) stimulated with PE (10-6.0 
M). 
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Supplement 2: Pilot work examining the effect of sodium salicylate (SS) and AMPK 
inhibition on relaxation in isolated SHR CCA segments (E+) stimulated with PE (10-6.0 
M). 
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Supplement 3: Force readout confirming the lack of endothelium (E-) in CCA preparation. After the addition of PE (10-6.0 M), ACh 
was administered in a dose-dependent fashion (10-8.0 – 10-4.0 M) and no contraction was elicited, indicating the segment was denuded. 
  
PE 
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Supplement 4: Pilot work examining the effect of sodium salicylate incubation and 
AMPK inhibition on PE-induced contraction. Vessels were incubated with sodium 
salicylate (SS; 10-2.5 M) and/or the AMPK inhibitor Compound C (CC; 20 µM).
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